Revance Therapeutics Inc (NASDAQ:RVNC) CFO Lauren P. Silvernail sold 20,000 shares of the business’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $32.00, for a total transaction of $640,000.00. Following the completion of the sale, the chief financial officer now owns 82,954 shares in the company, valued at approximately $2,654,528. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
NASDAQ:RVNC traded down $0.95 during mid-day trading on Monday, hitting $29.85. 398,673 shares of the stock traded hands, compared to its average volume of 350,542. The company has a market capitalization of $1,131.36, a price-to-earnings ratio of -7.37 and a beta of 1.33. Revance Therapeutics Inc has a 52 week low of $18.42 and a 52 week high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.15). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The business’s revenue for the quarter was down 50.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.95) earnings per share. analysts predict that Revance Therapeutics Inc will post -3.56 earnings per share for the current fiscal year.
Several analysts have commented on RVNC shares. ValuEngine cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Guggenheim cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Piper Jaffray upped their target price on shares of Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday, December 5th. Zacks Investment Research cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Finally, Cantor Fitzgerald set a $50.00 target price on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $45.17.
A number of hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in Revance Therapeutics in the 4th quarter worth about $392,000. Cowen Inc. bought a new position in Revance Therapeutics in the 4th quarter worth about $225,000. Jane Street Group LLC bought a new position in Revance Therapeutics in the 4th quarter worth about $685,000. 1492 Capital Management LLC bought a new position in Revance Therapeutics in the 4th quarter worth about $1,393,000. Finally, TIAA CREF Investment Management LLC grew its stake in Revance Therapeutics by 4.6% in the 4th quarter. TIAA CREF Investment Management LLC now owns 62,863 shares of the biopharmaceutical company’s stock worth $2,247,000 after acquiring an additional 2,759 shares in the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Revance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 20,000 Shares of Stock” was published by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://theenterpriseleader.com/2018/04/02/revance-therapeutics-inc-rvnc-cfo-sells-640000-00-in-stock.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.